Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
TFX 
Teleflex Incorporated (TFX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
01/09/2026: TFX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
14 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $131.29
1 Year Target Price $131.29
| 0 | Strong Buy |
| 2 | Buy |
| 11 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -32.14% | Avg. Invested days 32 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 01/09/2026 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 4.99B USD | Price to earnings Ratio - | 1Y Target Price 131.29 |
Price to earnings Ratio - | 1Y Target Price 131.29 | ||
Volume (30-day avg) 14 | Beta 0.93 | 52 Weeks Range 102.26 - 183.89 | Updated Date 01/10/2026 |
52 Weeks Range 102.26 - 183.89 | Updated Date 01/10/2026 | ||
Dividends yield (FY) 1.24% | Basic EPS (TTM) -7.17 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -10.28% | Operating Margin (TTM) 12.4% |
Management Effectiveness
Return on Assets (TTM) 4.94% | Return on Equity (TTM) -7.9% |
Valuation
Trailing PE - | Forward PE 7.29 | Enterprise Value 7276983824 | Price to Sales(TTM) 1.56 |
Enterprise Value 7276983824 | Price to Sales(TTM) 1.56 | ||
Enterprise Value to Revenue 2.28 | Enterprise Value to EBITDA 139.03 | Shares Outstanding 44194408 | Shares Floating 41709356 |
Shares Outstanding 44194408 | Shares Floating 41709356 | ||
Percent Insiders 0.33 | Percent Institutions 108 |
Upturn AI SWOT
Teleflex Incorporated
Company Overview
History and Background
Teleflex Incorporated was founded in 1943 as Teleflex Systems Company, initially focused on producing flexible shaft controls for aircraft. Over decades, it evolved through strategic acquisitions and organic growth into a global provider of medical technologies. Key milestones include its expansion into the medical device market, its listing on the New York Stock Exchange (NYSE: TFX), and its ongoing focus on developing innovative solutions for healthcare challenges.
Core Business Areas
- Vascular Access: This segment provides a broad range of products designed for vascular access, including PICC lines, central venous catheters, and arterial catheters, crucial for drug delivery, fluid management, and patient monitoring.
- Interventional Cardiology and Peripheral Therapy: This area focuses on devices used in the treatment of cardiovascular diseases, including catheters, guidewires, and access sheaths for minimally invasive procedures in the heart and peripheral arteries.
- Anesthesia and Respiratory Care: This segment offers products for respiratory support and anesthesia delivery, such as respiratory circuits, breathing systems, and airway management devices.
- Surgical: This segment includes a variety of surgical instruments and devices, such as advanced wound care solutions, surgical sealants, and general surgical instruments.
Leadership and Structure
Teleflex Incorporated is led by a Board of Directors and an executive management team. The Chief Executive Officer (CEO) oversees the company's strategic direction and operations. The organizational structure is typically divided by business segments and geographical regions to manage its global operations effectively.
Top Products and Market Share
Key Offerings
- Description: A comprehensive portfolio of central venous catheters, peripherally inserted central catheters (PICCs), and other vascular access devices used in critical care, oncology, and long-term IV therapy. Competitors include Becton Dickinson (BD), Medtronic, and Boston Scientific.
- Product Name: Arrowu00ae Vascular Access Products
- Description: A range of airway management devices that are critical in anesthesia and respiratory care. Teleflex is a significant player in this market. Competitors include Medtronic and various smaller medical device manufacturers.
- Product Name: Laryngeal Mask Airways (LMAs)
- Description: Teleflex provides a wide array of custom-designed medical tubing for various applications across its segments. This is a foundational offering supporting many of its other product lines. Competitors are numerous in the specialized tubing manufacturing space.
- Product Name: Customized Medical Tubing
Market Dynamics
Industry Overview
Teleflex operates in the global medical device industry, which is characterized by innovation, regulatory scrutiny, and a growing demand for minimally invasive and advanced healthcare solutions. Key trends include an aging global population, increasing prevalence of chronic diseases, and a focus on cost-efficiency in healthcare delivery.
Positioning
Teleflex is positioned as a global provider of medical technologies, focusing on delivering innovative solutions that improve patient outcomes and reduce the cost of care. Its competitive advantages lie in its diverse product portfolio, established distribution channels, and a history of strategic acquisitions that expand its market reach and technological capabilities.
Total Addressable Market (TAM)
The total addressable market for Teleflex is substantial, encompassing various segments of the global medical device market. While precise TAM figures vary by specific product category, the overall medical device market is valued in hundreds of billions of dollars globally. Teleflex aims to capture a significant share of its target sub-segments within this broad market through its specialized offerings.
Upturn SWOT Analysis
Strengths
- Diversified product portfolio across multiple medical specialties.
- Strong global distribution network and established customer relationships.
- Reputation for innovation and quality in its product offerings.
- History of successful strategic acquisitions to expand capabilities and market access.
Weaknesses
- Reliance on a few key product lines and potential for competitive disruption.
- Integration challenges and costs associated with recent acquisitions.
- Potential impact of product recalls or regulatory issues on revenue and reputation.
- Susceptibility to fluctuations in healthcare spending and reimbursement policies.
Opportunities
- Growing demand for minimally invasive medical devices.
- Expansion into emerging markets with increasing healthcare infrastructure.
- Leveraging technology for remote patient monitoring and telehealth solutions.
- Developing new products to address unmet clinical needs in critical care and interventional therapies.
Threats
- Intense competition from larger and more specialized medical device companies.
- Increasingly stringent regulatory requirements and compliance costs.
- Pricing pressures from healthcare providers and payers.
- Global economic downturns impacting healthcare spending.
- Supply chain disruptions and raw material cost volatility.
Competitors and Market Share
Key Competitors
- Becton, Dickinson and Company (BD)
- Medtronic plc (MDT)
- Boston Scientific Corporation (BSX)
- Abbott Laboratories (ABT)
- Cardinal Health, Inc. (CAH)
Competitive Landscape
Teleflex competes in a highly competitive medical device market. Its advantages include a broad product range and a strong presence in specific niches. However, it faces competition from larger, more diversified players with greater R&D budgets and established market dominance in certain areas. Strategic acquisitions are crucial for Teleflex to maintain its competitive edge and expand its market share.
Major Acquisitions
Vascular Solutions, Inc.
- Year: 2016
- Acquisition Price (USD millions): 1000
- Strategic Rationale: Acquisition expanded Teleflex's presence in the cardiology and peripheral vascular markets, adding complementary products and technologies.
NeoTract
- Year: 2018
- Acquisition Price (USD millions): 1000
- Strategic Rationale: This acquisition strengthened Teleflex's urology portfolio, particularly in the treatment of Benign Prostatic Hyperplasia (BPH) with its UroLift System.
Growth Trajectory and Initiatives
Historical Growth: Teleflex has experienced steady historical growth, largely fueled by a strategy of acquiring complementary medical device businesses and expanding its product offerings into higher-growth markets. Organic growth has also been a contributing factor, driven by product innovation and market penetration.
Future Projections: Analyst projections for Teleflex generally anticipate continued revenue growth, supported by its expanding product pipeline and strategic market positioning. Growth is expected to be driven by advancements in its key business segments, particularly in interventional cardiology and vascular access. The company is also expected to continue exploring strategic acquisition opportunities.
Recent Initiatives: Recent initiatives by Teleflex have focused on optimizing its product portfolio, divesting non-core assets, and investing in innovation within its key medical technology segments. The company has also been focused on streamlining operations and improving its supply chain efficiency.
Summary
Teleflex Incorporated is a well-established medical device company with a diverse product portfolio and a global reach. Its strengths lie in its innovation, distribution, and strategic acquisition history, driving consistent revenue growth. However, it faces intense competition and regulatory challenges, requiring continuous adaptation. The company is well-positioned to capitalize on the growing demand for advanced healthcare solutions but must navigate pricing pressures and potential market disruptions effectively.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Teleflex Incorporated Investor Relations
- SEC Filings (10-K, 10-Q)
- Financial News Outlets (e.g., Bloomberg, Reuters, Wall Street Journal)
- Industry Analysis Reports
Disclaimers:
This JSON output is for informational purposes only and does not constitute financial advice. Market share data is an estimation based on available industry reports and may not reflect precise figures. All financial data is based on publicly reported information and is subject to change. Investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Teleflex Incorporated
Exchange NYSE | Headquaters Wayne, PA, United States | ||
IPO Launch date 1988-02-18 | CEO - | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 14100 | Website https://www.teleflex.com |
Full time employees 14100 | Website https://www.teleflex.com | ||
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous bone access systems for the administration of intravenous therapies, the measurement of blood pressure, and the collection of blood samples. The company also offers interventional products, including various coronary catheters, structural heart support devices, peripheral intervention products, and mechanical circulatory support platform; and Arrow branded intra-aortic balloon pumps and catheters, Guideliner, Turnpike, and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. It provides anesthesia products, such as airway, pain management, and hemostatic products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligating clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. The company also offers interventional urology products comprising the UroLift System, an invasive technology for treating lower urinary tract symptoms; respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings; urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology, as well as bladder management services; and OEM products, which includes the TFX Medical OEM, TFX OEM, Deknatel, and HPC Medical brands. It serves hospitals and healthcare providers, medical device manufacturers, and home care markets. Teleflex Incorporated was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.